Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.
Anticoagulants are used for the treatment of DVT or PE, to prevent recurrence and to reduce the risk of secondary complications, such as post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH).1-3
The phases of anticoagulation treatment may be categorised as ‘active’ and ‘long-term’.4 The first phase is considered to be active treatment of acute VTE and secondary prevention, whereas the second phase is considered to be secondary prevention only.4
Phases of anticoagulation treatment for VTE4,5
Adapted from Kearon et al. 2012.4
The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.5 All prescribing must be in accordance with the appropriate SmPC.
More information on anticoagulants for the treatment of VTE and secondary prevention of VTE is provided later.
Adverse events should be reported. Reporting forms and information can be found via United Kingdom – The yellow card scheme at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via email@example.com or 0800 731 1736 (United Kingdom).
This link takes you to a third party website that is part of the Bristol-Myers Squibb Group and Pfizer Group. The Alliance (Bristol Myers Squibb Group and Pfizer Group) recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it. If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.